Blocking Two Growth Factors to Fight Colon Cancer
Author Information
Author(s): Shaheen R M, Ahmad S A, Liu W, Reinmuth N, Jung Y D, Tseng W W, Drazan K E, Bucana C D, Hicklin D J, Ellis L M
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
Simultaneous blockade of the VEGF and EGF receptors would enhance the therapy of colon cancer in a mouse model of peritoneal carcinomatosis.
Conclusion
Combining anti-VEGF and anti-EGFR therapy may provide a new way to treat colon cancer that has spread to the peritoneum.
Supporting Evidence
- Treatment with DC101 or DC101+C225 decreased tumor vascularity and growth compared to the control group.
- DC101 combined with C225 led to a significant decrease in tumor vascularity and increased apoptosis of tumor and endothelial cells.
Takeaway
Researchers found that using two different treatments together can help stop colon cancer from growing and spreading in mice.
Methodology
Nude mice were injected with human colon cancer cells and treated with different combinations of anti-VEGF and anti-EGFR antibodies.
Participant Demographics
Nude mice were used in the study.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website